Since December 2019, the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has resulted in high morbidity and mortality worldwide. New York State emerged as an epicenter of the outbreak in the United States, with more than 348,000 cases of laboratory-confirmed SARS-CoV-2 infection as of May 10, 2020.^[@r1]^ Globally and in New York State, initial reports indicated that children typically have mild or no Covid-19 symptoms and have lower rates of hospitalization and death than adults.^[@r3]^ However, in early May, the United Kingdom and several European countries reported the occurrence of a hyperinflammatory process in children that had features similar to atypical Kawasaki's disease, Kawasaki's disease shock syndrome, and toxic shock syndrome, possibly related to SARS-CoV-2 infection.^[@r8]^ On May 13, 2020, the New York State Department of Health (NYSDOH) released an interim case definition,^[@r13]^ and on May 14, 2020, the Centers for Disease Control and Prevention (CDC) released a Health Alert Network advisory about multisystem inflammatory syndrome in children (MIS-C) associated with Covid-19.^[@r14]^

Between January 1 and May 10, 2020, the NYSDOH received reports of 15,515 cases of SARS-CoV-2 infection detected by reverse-transcriptase--polymerase-chain-reaction (RT-PCR) assay among children and adolescents younger than 21 years of age; 816 patients (5%) were hospitalized with acute Covid-19, and 14 (0.1%) died.^[@r3]^ After the initial reports of suspected cases of MIS-C in early May, the NYSDOH established active, statewide surveillance to rapidly ascertain cases of possible MIS-C from hospitals through daily required reporting.

We describe the demographic characteristics, presenting symptoms, clinical course, laboratory findings, therapy received, and outcomes among children and adolescents meeting the NYSDOH case definition of MIS-C. We also examine the temporal relationship between the Covid-19 outbreak in New York State and reported cases of MIS-C.

Methods {#sc1}
=======

Data Reporting {#sc1.1}
--------------

Reporting and investigation of reportable communicable diseases, including SARS-CoV-2 (and its complications, such as MIS-C), are mandated under New York State Public Health Law.^[@r15]^ Data were collected as part of a public health response; human research protection review at the CDC determined that institutional-review-board review was not required.

Data Sources {#sc1.2}
------------

On May 5, 2020, the NYSDOH required 106 hospitals in New York State that provide pediatric medical or surgical care to report potential cases of MIS-C among persons younger than 21 years of age admitted since March 1, 2020, through the NYSDOH Health Emergency Response Data System. Hospitals were asked to identify and submit medical records for patients who received a diagnosis of Kawasaki's disease, toxic shock syndrome, or myocarditis or who were suspected to have MIS-C. The NYSDOH Electronic Clinical Laboratory Reporting System (ECLRS) was used to collect data on the results of RT-PCR or serologic tests for SARS-CoV-2 from reported patients.

Case Definition {#sc1.3}
---------------

On May 13, 2020, the NYSDOH established an interim case definition of MIS-C (Fig. S1 in the [Supplementary Appendix](#ap1){ref-type="app"}, available with the full text of this article at NEJM.org). Confirmed cases were defined by the presence of both clinical and laboratory criteria. Laboratory evidence consisted of elevated levels of two or more inflammatory markers and virologic evidence (any positive molecular test for SARS-CoV-2) or serologic evidence within 10 days after admission (reactivity for IgG or IgM antibodies against SARS-CoV-2). For this evaluation, patients without supportive virologic laboratory evidence of SARS-CoV-2 were categorized as having a suspected case if they met clinical criteria and had exposure to a person with Covid-19 in the 6 weeks before hospitalization.

Standardized Study Definitions {#sc1.4}
------------------------------

We defined values for tachycardia, tachypnea, hypotension, lymphopenia, neutropenia, and elevated levels of pro--brain natriuretic peptide (proBNP) (all during the first 24 hours of admission) on the basis of age standards.^[@r16]^ Myocarditis was determined by discharge diagnosis or the code in the *International Classification of Diseases, 10th Revision*. Clinical myocarditis was defined as cardiac dysfunction on echocardiography with an elevated troponin level; if troponin levels were not tested, clinical myocarditis was defined as elevated levels of proBNP or brain natriuretic peptide and cardiac dysfunction (defined as any ventricular dysfunction or hypokinesia or decreased contractility or ejection fraction) or arrhythmia on electrocardiography. Coronary-artery aneurysm was reported on the basis of echocardiographic findings and z scores (Boston criteria, when available).

Study Sample {#sc1.5}
------------

Using a modified version of the CDC Covid-19 standardized case-report form, a trained team of physicians, nurses, and epidemiologists abstracted demographic information, clinical characteristics, laboratory values, hospital course, treatment, and outcomes from possible cases among patients admitted from March 1 through May 10, 2020. Presenting signs and symptoms were classified as constitutional (fever, subjective fever, or chills), cardiovascular (chest pain), gastrointestinal (abdominal pain, nausea, vomiting, or diarrhea), dermatologic (rash or swelling of fingers, hands, toes, or feet), mucocutaneous (conjunctival injection or mucosal changes), neurologic (headache, altered mental status, or confusion), lymphadenopathy, musculoskeletal (myalgias or arthralgias), upper respiratory (congestion or sore throat), or lower respiratory (cough, shortness of breath, or wheezing).

Statistical Analysis {#sc1.6}
--------------------

Medians and interquartile ranges for continuous variables and frequencies and proportions for categorical variables were calculated with the use of SAS software, version 9.4 (SAS Institute). Patient age was grouped into three categories: less than 6 years, 6 to 12 years, and 13 to 20 years. The NYSDOH ECLRS laboratory data were used to calculate the incidence of laboratory-confirmed Covid-19 and to generate an epidemiologic curve of laboratory-confirmed cases of Covid-19 among pediatric and adolescent patients according to the date of specimen collection, for comparison with the date of hospital admission among patients with MIS-C.

Authors at the NYSDOH designed and implemented the surveillance system and evaluation. All the authors participated in the data-collection process, analyzed the data, wrote the manuscript, made the decision to submit the manuscript for publication, and vouch for the completeness and accuracy of the data. Data were collected as part of public health reporting of communicable disease, and the confidentiality of the data were maintained by the NYSDOH.

Results {#sc2}
=======

Study Population and SARS-CoV-2 Testing {#sc2.1}
---------------------------------------

From March 1 through May 10, 2020, there were 191 reports submitted to the NYSDOH regarding admitted patients younger than 21 years of age. A total of 189 medical records were received, and 161 were abstracted (Fig. S2). Of these 161 patients, 99 met the NYSDOH interim case definition of MIS-C (for comparison of included and excluded patients, see Table S1); 95 patients (96%) were classified as having a confirmed case and 4 (4%) as having a suspected case. Of the 99 patients, 29 (29%) met clinical criteria with one or more of the following: hypotension or shock, severe cardiac illness, or other severe end-organ illness; 6 (6%) met clinical criteria with two or more of the following: rash, conjunctivitis, mucocutaneous signs, or gastrointestinal symptoms; and 64 (65%) met both types of clinical criteria. Between March 1 to May 10, of the 95 patients with confirmed cases, 94 (99%) were tested for SARS-CoV-2 infection with an RT-PCR assay and 77 (81%) were tested for the presence of SARS-CoV-2 antibodies with a serologic assay; 19 (20%) had evidence of SARS-CoV-2 infection from an RT-PCR assay alone, 45 (47%) had evidence of SARS-CoV-2 infection from a serologic assay alone (1 of whom was never tested for SARS-CoV-2 infection with an RT-PCR assay), and 31 (33%) had evidence of SARS-CoV-2 from both RT-PCR and serologic assays. Of the 77 patients tested for the presence of IgG, 76 (99%) were reactive; 3 patients were reactive for IgA, 3 were reactive for IgM, and 21 were nonreactive for IgM. There were no patients with IgM or IgA reactivity alone. Of the 76 patients with serologic evidence of SARS-CoV-2 infection, 40 (53%) had reactive IgG before or on the first day of admission.

All four patients with suspected cases had negative molecular testing; none underwent serologic testing. Two (50%) had Covid-19--like illness in the 6 weeks before MIS-C symptom onset. Because the characteristics of the patients with confirmed cases and of the patients with suspected cases were similar (data not shown), the two groups were combined for further analyses.

Characteristics of the Patients {#sc2.2}
-------------------------------

Of the 99 patients with MIS-C, 53 (54%) were male. A total of 31 patients (31%) were 0 to 5 years of age, 42 (42%) were 6 to 12 years of age, and 26 (26%) were 13 to 20 years of age ([Table 1](#t1){ref-type="table"}). Of 78 patients with data on race, 29 (37%) were white, 31 (40%) were black, 4 (5%) were Asian, and 14 (18%) were of other races; of 85 patients with data on ethnic group, 31 (36%) were Hispanic ([Table 2](#t2){ref-type="table"}). Of the 36 patients with a preexisting condition, 29 had obesity. All the patients had fever or chills at admission. Other common presenting symptoms were gastrointestinal (80%), dermatologic (62%), mucocutaneous (61%), and lower respiratory (40%). A total of 60 patients (61%) had gastrointestinal and either dermatologic or mucocutaneous symptoms. [Figure 1](#f1){ref-type="fig"} shows symptom categories according to age group. Neurologic symptoms, predominantly headache, were present in 13% of the patients 0 to 5 years of age and 38% of those 13 to 20 years of age. A total of 48% of the patients 0 to 5 years of age and 43% of those 6 to 12 years of age presented with Kawasaki's disease or atypical Kawasaki's disease, whereas 12% of those 13 to 20 years of age had such a presentation.

One neonate, who was classified as having a suspected case and whose mother had asymptomatic SARS-CoV-2 infection at delivery, presented with fever and left breast cellulitis between 14 and 28 days of age. Laboratory assessment showed increasing troponin levels (increasing from 43 ng per liter to 51 ng per liter in 10 hours); cardiac two-dimensional ultrasonography showed good ventricular function and unremarkable coronary arteries. Two molecular tests for SARS-CoV-2 were negative. The discharge diagnoses were cellulitis, myocarditis, and shock. One adolescent who was pregnant (between 23 and 26 weeks of gestation), classified as having a confirmed case, was admitted with fever, headache, and chest pain. She had hypotension, and laboratory assessment showed elevated levels of troponin and other inflammatory markers. The discharge diagnoses were acute respiratory distress syndrome, perimyocarditis, and pneumonia.

On admission, 63% of the patients had fever of 38.0°C (100.4°F) or higher, 97% had tachycardia, 78% had tachypnea, and 32% had hypotension ([Table 3](#t3){ref-type="table"}). The median temperature on admission was 38.3°C, and the median oxygen saturation was 98%. Median and interquartile ranges for systolic and diastolic blood-pressure measurements at admission, according to age, are presented in Table S2. On admission, among patients with suspected or confirmed MIS-C, the median white-cell count was 10,400 per microliter, and 59 of 89 (66%) had lymphopenia; 74 of 82 (90%) had elevated proBNP levels, 63 of 89 (71%) had elevated troponin levels, 98 of 98 had elevated C-reactive protein levels, and 86 of 94 (91%) had elevated [d]{.smallcaps}-dimer levels ([Table 3](#t3){ref-type="table"}). Additional clinical and laboratory findings on admission, according to age group, are provided in [Table 2](#t2){ref-type="table"} and [Table 3](#t3){ref-type="table"}.

Antecedent Illness and Viral and Bacterial Testing on Admission {#sc2.3}
---------------------------------------------------------------

In the 6 weeks before admission, of the 99 patients with MIS-C, 24 (24%) had a Covid-19--compatible illness a median of 21 days (interquartile range, 10 to 31) before hospitalization, 38 (38%) had exposure to a person with confirmed Covid-19, and 22 (22%) had direct contact with a person who had a clinically compatible Covid-19--like illness. Testing for respiratory viruses, including influenza A and B, and for respiratory syncytial virus was performed in 57 patients (58%). Of the 57 patients tested for respiratory viruses, 2 had evidence of viral infection: coronavirus 229e and SARS-CoV-2 were detected in 1 patient, and adenovirus, a nontyped coronavirus, and SARS-CoV-2 were detected in 1 patient. Bacterial cultures were reported for 77 patients (78%); none showed evidence of a bacterial blood infection. A total of 71 patients (72%) received empiric systemic antibacterial therapy.

Clinical Course, Treatment, and Outcomes {#sc2.4}
----------------------------------------

Overall, 79 patients (80%) were admitted to an intensive care unit (ICU) (median time from admission to ICU entry, \<1 day; interquartile range, 0 to 1), and 10 (10%) received mechanical ventilation. The median time from symptom onset to hospital admission was 4 days (interquartile range, 3 to 6) ([Table 4](#t4){ref-type="table"}). A total of 69 patients (70%) received intravenous immune globulin (IVIG), 63 (64%) received systemic glucocorticoids, and 61 (62%) received vasopressor support; 48 (48%) received both systemic glucocorticoids and IVIG. During hospitalization, at least one echocardiogram was obtained for 93 patients (94%); 51 (52%) had some degree of ventricular dysfunction, 32 (32%) had pericardial effusion, and 9 (9%) had a documented coronary-artery aneurysm. The z scores were reported for 7 of the 9 patients with coronary-artery aneurysms, with 4 (57%) having a score of 2.5 to less than 5. Of 60 patients with examinations for troponin and proBNP levels, an electrocardiogram, and an echocardiogram, 59 had evidence of cardiac abnormalities. Of 90 patients who underwent computed tomography (CT) or radiography of the chest, 35 (39%) had at least one opacity noted. Of 44 patients who underwent CT of the abdomen, ultrasonography of the abdomen, or both, 34 (77%) had abnormal findings; 4 (9%) had hepatomegaly, splenomegaly, or hepatosplenomegaly, 8 (18%) had mesenteric adenopathy, 16 (36%) had ascites, pleural effusions, or pelvic fluid, and 17 (39%) had inflammation or enlargement of the appendix (in 2 patients) or the gallbladder (in 5), enteritis or enterocolitis (in 3), bowel-wall thickening (in 7), or fluid-filled bowel loops (in 4).

A total of 36 patients (36%) received a diagnosis of Kawasaki's disease or atypical (or incomplete) Kawasaki's disease; 7 of the 9 patients with coronary-artery aneurysms also received a diagnosis of Kawasaki's disease. A total of 36 patients (36%) received a diagnosis of myocarditis, and an additional 16 (16%) had clinical myocarditis. As of May 15, a total of 76 patients (77%) had been discharged and 21 (21%) were still hospitalized; 2 (2%) died in the hospital. The median length of stay was 6 days (interquartile range, 4 to 9) overall, 6 days (interquartile range, 4 to 8) among patients who were discharged, and 7 days (interquartile range, 3 to 11) among those who died.

Death occurred in two children 0 to 12 years of age. Both were admitted with abdominal pain and fever, had tachycardia and hypotension on presentation, and during the course of their hospitalization received vasopressor support and underwent intubation; one received extracorporeal membrane oxygenation. Neither received IVIG, systemic glucocorticoids, or immunomodulators. The contributing cause of death for both children included complications of a possibly inflammatory, coagulopathic, or neurologic process.

Epidemic Curve {#sc2.5}
--------------

Cases of laboratory-confirmed SARS-CoV-2 infection among persons younger than 21 years of age in New York State, according to date of specimen collection, and cases of confirmed and suspected MIS-C in our study, according to date of admission, are shown in [Figure 2](#f2){ref-type="fig"}. The peak in the number of MIS-C cases followed the peak in the number of cases of laboratory-confirmed SARS-CoV-2 infection by 31 days. From March 1 through May 10, 2020, the incidence of laboratory-confirmed SARS-CoV-2 infection was 322 per 100,000 persons younger than 21 years of age, and the incidence of MIS-C was 2 per 100,000 persons younger than 21 years of age.

Discussion {#sc3}
==========

Our study involving hospitalized pediatric patients with MIS-C in New York State describes a febrile hyperinflammatory syndrome with dermatologic, mucocutaneous, and gastrointestinal manifestations associated with cardiac dysfunction; this syndrome is currently being seen worldwide. Although 32% of the patients had hypotension at admission, 62% (48% of those 0 to 5 years of age) received vasopressor support and 80% were admitted to an ICU. Notable findings were the high prevalence of cardiac dysfunction or depression, coagulopathy, and gastrointestinal symptoms, accompanied by mild respiratory symptoms and occasional indications for supplemental oxygen, in contrast with most cases of acute Covid-19 among hospitalized children.^[@r4],[@r19]^ Patients were commonly treated with IVIG, glucocorticoids, and vasopressors. This constellation suggests an inflammatory vasculopathy, with some similarities to Kawasaki's disease and toxic shock syndrome. Our findings are consistent with those of other studies to date, which have been limited to case reports, short reports, and small case series.^[@r10],[@r11],[@r20]^

As in a study from Italy, MIS-C cases in New York State followed the peak of the Covid-19 epidemic in the state, which supports a temporal and geographic association between Covid-19 and MIS-C.^[@r10]^ Of the patients tested with a serologic assay, nearly all had reactivity, and of the 76 who were tested with both RT-PCR and serologic assays for SARS-CoV-2, 44 (58%) had only serologic evidence of current or recent SARS-CoV-2 infection, which supports a laboratory-based association. Of the 4 patients with suspected cases, none of whom had laboratory evidence of SARS-CoV-2 infection on admission, 2 (50%) had had a Covid-19--like illness in the 6 weeks before MIS-C symptom onset. These findings support that MIS-C is probably a postinfectious, inflammatory process related to Covid-19.

We found variations in presenting symptoms and manifestations according to age. The prevalence of dermatologic symptoms was highest among children 0 to 5 years of age, and the prevalence of myocarditis (diagnoses and clinical) was highest among the adolescents. The prevalence of gastrointestinal symptoms was high in all age groups. Nearly half of children 0 to 5 years of age with MIS-C but only 12% of the adolescents 13 to 20 years of age had a discharge diagnosis of Kawasaki's disease or atypical Kawasaki's disease. Children 0 to 12 years of age with MIS-C were more likely to present with Kawasaki's disease--like symptoms such as conjunctival injection, rash, and oral mucosal changes than adolescents with MIS-C; however, children 0 to 12 years of age in our study presenting with Kawasaki's disease--like symptoms were older, were more likely to present with hypotension, and were more commonly admitted to the ICU than children with Kawasaki's disease described in previous reports.^[@r25]^ Although Kawasaki's disease--like symptoms were less common among adolescents than among younger children with MIS-C, they did still occur, and rare cases of Kawasaki's disease among adults have been reported.^[@r26]^ Further research could explore whether a post--SARS-CoV-2 inflammatory syndrome exists in adults.

Although classic Kawasaki's disease disproportionately affects Asian children, MIS-C that is associated with Covid-19 appears to occur among children of all racial and ethnic backgrounds.^[@r24]^ Among our patients, predominantly from the New York Metropolitan Region, 40% were black and 36% were Hispanic. This may be a reflection of the well-documented elevated incidence of SARS CoV-2 infection among black and Hispanic communities.^[@r6],[@r27]^ In comparison, among persons younger than 21 years of age, an estimated 25% and 32% of people living in the New York Metropolitan Region in 2018 were black and Hispanic, respectively.^[@r28]^

Limitations of our study include presumed underestimation, possibly due to mild cases of MIS-C that did not involve hospitalization, and possible underreporting due to lack of recognition of an emerging syndrome. Furthermore, clinicians may not have ordered a full panel of inflammatory markers, possibly excluding some patients. Children with severe acute Covid-19 who had a concurrent inflammatory syndrome^[@r29]^ complicating their hospitalization may have met the case definition, which would dilute our understanding of MIS-C. In addition, the lack of serologic tests early in the outbreak, limited availability of molecular or serologic testing, and clinician testing practices in children may have led to underrecognition. This may have been particularly true for those excluded because they did not meet the virologic or epidemiologic criteria; the clinical and laboratory characteristics of these patients were more similar to the characteristics of patients with MIS-C than they were to the characteristics of patients excluded for other reasons. However, others not meeting the virologic or epidemiologic criteria may represent patients with baseline Kawasaki's disease, particularly in geographic areas without ongoing community-based transmission of SARS-CoV-2. The sensitivity or specificity of the case definition for confirmed MIS-C may be further affected by the varying performance of both PCR and serologic tests according to manufacturer and setting. We could not independently verify the diagnosis of Kawasaki's disease, atypical Kawasaki's disease, or toxic shock syndrome.

Although most children have mild or no illness from SARS-CoV-2 infection, MIS-C may follow Covid-19 or asymptomatic SARS-CoV-2 infection. Recognition of the syndrome and early identification of children with MIS-C, including early monitoring of blood pressure and electrocardiographic and echocardiographic evaluation, could inform appropriate supportive care and other potential therapeutic options.^[@r10],[@r11]^

Because children often present with mild symptoms of Covid-19 and are less frequently tested than adults,^[@r4],[@r7]^ the incidence of MIS-C among children infected with SARS-CoV-2 is unclear. It is crucial to establish surveillance for MIS-C cases,^[@r14]^ particularly in communities with higher levels of SARS-CoV-2 transmission.

[Disclosure forms](#ap2){ref-type="app"} provided by the authors are available with the full text of this article at NEJM.org.
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![Syndrome Clusters According to Age Group among Patients with Multisystem Inflammatory Syndrome in Children (MIS-C).\
Color ranges were determined at quintiles of the observed percentages. Dermatologic or mucocutaneous included the following symptoms: rash, conjunctivitis, swollen hands or feet, and mucosal changes. Gastrointestinal included the following symptoms: abdominal pain, nausea or vomiting, and diarrhea. Kawasaki's disease (KD) or atypical KD was determined by discharge diagnosis or code in the *International Classification of Diseases, 10th Revision* (ICD-10). Myocarditis was determined by discharge diagnosis or ICD-10 code. Clinical myocarditis was defined as cardiac dysfunction on echocardiography with an elevated troponin level; if the troponin value was missing, clinical myocarditis was defined as an elevated level of pro--brain natriuretic peptide or brain natriuretic peptide and cardiac dysfunction or arrhythmia on electrocardiography in the context of an inflammatory process. Neurologic included the following symptoms: headache, altered mental status, and confusion.](NEJMoa2021756_f1){#f1}

![Pediatric Cases of Coronavirus Disease 2019 (Covid-19) and of MIS-C.\
All data are for patients younger than 21 years of age in New York State from March through May, 2020. Covid-19 was defined by a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).](NEJMoa2021756_f2){#f2}

###### Patients at Hospital Admission with Confirmed or Suspected Multisystem Inflammatory Syndrome in Children (MIS-C).[\*](#t1fn1){ref-type="table-fn"}

![](NEJMoa2021756_t1)

  -----------------------------------------------------------------
  Characteristic   Overall\   Confirmed MIS-C\   Suspected MIS-C\
                   (N=99)     (N=95)             (N=4)
  ---------------- ---------- ------------------ ------------------
  Male sex         53 (54)    51 (54)            2 (50)

  Age                                            

  0--5 yr          31 (31)    27 (28)            4 (100)

  6--12 yr         42 (42)    42 (44)            0

  13--20 yr        26 (26)    26 (27)            0
  -----------------------------------------------------------------

Percentages may not total 100 because of rounding.

###### Demographic and Clinical Characteristics of the Patients at Hospital Admission, According to Age Group.[\*](#t2fn1){ref-type="table-fn"}

![](NEJMoa2021756_t2)

  ------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                                       Overall\     0--5 Years\   6--12 Years\   13--20 Years\
                                                                       (N=99)       (N=31)        (N=42)         (N=26)
  -------------------------------------------------------------------- ------------ ------------- -------------- ---------------
  Positivity for SARS-CoV-2 --- no./total no. (%)                                                                

  On RT-PCR assay                                                      50/98 (51)   15/31 (48)    19/41 (46)     16/26 (62)

  On serologic assay for IgG antibodies                                76/77 (99)   24/25 (96)    33/33 (100)    19/19 (100)

  Male sex --- no. (%)                                                 53 (54)      20 (65)       18 (43)        15 (58)

  Race --- no./total no. (%)[†](#t2fn2){ref-type="table-fn"}                                                     

  White                                                                29/78 (37)   10/27 (37)    13/34 (38)     6/17 (35)

  Black                                                                31/78 (40)   13/27 (48)    12/34 (35)     6/17 (35)

  Asian                                                                4/78 (5)     0/27          2/34 (6)       2/17 (12)

  Other[‡](#t2fn3){ref-type="table-fn"}                                14/78 (18)   4/27 (15)     7/34 (21)      3/17 (18)

  Ethnic group --- no./total no. (%)[†](#t2fn2){ref-type="table-fn"}                                             

  Hispanic                                                             31/85 (36)   12/28 (43)    11/35 (31)     8/22 (36)

  Not Hispanic                                                         54/85 (64)   16/28 (57)    24/35 (69)     14/22 (64)

  Coexisting conditions --- no. (%)[§](#t2fn4){ref-type="table-fn"}                                              

  Any                                                                  36 (36)      10 (32)       14 (33)        12 (46)

  Chronic lung disease[¶](#t2fn5){ref-type="table-fn"}                 14 (14)      2 (6)         5 (12)         7 (27)

  Obesity                                                              29 (29)      10 (32)       11 (26)        8 (31)

  Symptoms at admission --- no. (%)                                                                              

  Constitutional: fever or chills                                      99 (100)     31 (100)      42 (100)       26 (100)

  Cardiovascular: chest pain                                           11 (11)      1 (3)         3 (7)          7 (27)

  Any gastrointestinal                                                 79 (80)      23 (74)       35 (83)        21 (81)

  Abdominal pain                                                       60 (61)      18 (58)       29 (69)        13 (50)

  Nausea or vomiting                                                   57 (58)      16 (52)       25 (60)        16 (62)

  Diarrhea                                                             49 (49)      13 (42)       23 (55)        13 (50)

  Any dermatologic                                                     61 (62)      24 (77)       25 (60)        12 (46)

  Rash                                                                 59 (60)      23 (74)       25 (60)        11 (42)

  Swollen hands or feet                                                9 (9)        6 (19)        1 (2)          2 (8)

  Any gastrointestinal and any dermatologic                            48 (48)      17 (55)       21 (50)        10 (38)

  Any mucocutaneous                                                    60 (61)      22 (71)       25 (60)        13 (50)

  Conjunctivitis                                                       55 (56)      21 (68)       23 (55)        11 (42)

  Mucosal changes                                                      27 (27)      15 (48)       8 (19)         4 (15)

  Any gastrointestinal and any mucocutaneous                           48 (48)      16 (52)       21 (50)        11 (42)

  Any neurologic                                                       30 (30)      4 (13)        16 (38)        10 (38)

  Headache                                                             29 (29)      4 (13)        15 (36)        10 (38)

  Altered mental status or confusion                                   2 (2)        0             1 (2)          1 (4)

  Lymphadenopathy                                                      6 (6)        4 (13)        2 (5)          0

  Any musculoskeletal                                                  20 (20)      2 (6)         9 (21)         9 (35)

  Muscle aches or myalgias                                             17 (17)      1 (3)         8 (19)         8 (31)

  Joint pain                                                           4 (4)        1 (3)         1 (2)          2 (8)

  Upper respiratory                                                    27 (27)      12 (39)       9 (21)         6 (23)

  Congestion                                                           13 (13)      8 (26)        2 (5)          3 (12)

  Sore throat                                                          16 (16)      5 (16)        8 (19)         3 (12)

  Lower respiratory                                                    40 (40)      13 (42)       14 (33)        13 (50)

  Cough                                                                31 (31)      11 (35)       11 (26)        9 (35)

  Shortness of breath                                                  19 (19)      5 (16)        6 (14)         8 (31)

  Wheezing                                                             1 (1)        1 (3)         0              0
  ------------------------------------------------------------------------------------------------------------------------------

IQR denotes interquartile range, RT-PCR reverse transcriptase--polymerase chain reaction, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.

Race and ethnic group were determined through medical-record review.

Other race included American Indian or Alaska Native or multiracial or other racial-ethnic group.

Among patients with confirmed MIS-C, 1 patient each had congenital heart disease, psoriatic arthritis, and adult-onset Still's disease during methotrexate treatment.

A total of 12 patients had asthma or reactive airway disease, 1 had oxygen dependence, and 1 was a former 25-week-premature infant.

###### Vital Signs and Laboratory Values of the Patients at Hospital Admission, According to Age Group.[\*](#t3fn1){ref-type="table-fn"}

![](NEJMoa2021756_t3)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                                                         Overall\              0--5 Years\         6--12 Years\          13--20 Years\
                                                                                         (N=99)                (N=31)              (N=42)                (N=26)
  -------------------------------------------------------------------------------------- --------------------- ------------------- --------------------- ---------------------
  **Vital signs**                                                                                                                                        

  Median heart rate (IQR) --- beats/min                                                  133 (120--148)        145 (130--158)      138 (123--153)        121 (116--130)

  Tachycardia --- no. (%)[†](#t3fn2){ref-type="table-fn"}                                96 (97)               28 (90)             42 (100)              26 (100)

  Median respiratory rate (IQR) --- breaths/min                                          27 (23--36)           31 (24--42)         26 (23--36)           26 (20--33)

  Tachypnea --- no. (%)[‡](#t3fn3){ref-type="table-fn"}                                  77 (78)               21 (68)             34 (81)               22 (85)

  Hypotension --- no. (%)[§](#t3fn4){ref-type="table-fn"}                                32 (32)               3 (10)              17 (40)               12 (46)

  Median temperature (IQR) --- °C                                                        38.3 (37.5--39.3)     38.3 (37.3--39.4)   38.4 (37.5--39.3)     38.3 (37.4--39.3)

  Temperature ≥38.0°C --- no. (%)[¶](#t3fn5){ref-type="table-fn"}                        62 (63)               19 (61)             27 (64)               16 (62)

  Median oxygen saturation (IQR) --- %                                                   98 (97--100)          98 (96--99)         99 (97--100)          98 (95--99)

  Oxygen saturation \<92% --- no. (%)                                                    4 (4)                 3 (10)              0                     1 (4)

  **Laboratory values[‖](#t3fn6){ref-type="table-fn"}**                                                                                                  

  Median white-cell count (IQR) --- ×10^−3^/μl                                           10.4 (6.7--14.5)      11.2 (7.4--14.8)    9.1 (6.4--13.7)       10.9 (8.0--14.0)

  Median lymphocyte level (IQR) --- %                                                    10.0 (5.0--16.0)      17.9 (11.7--23.0)   8.5 (4.0--12.0)       6.0 (4.0--11.3)

  Lymphopenia --- no./total no. (%)[\*\*](#t3fn7){ref-type="table-fn"}                   59/89 (66)            11/27 (41)          29/38 (76)            19/24 (79)

  Median neutrophil level (IQR) --- %                                                    82.0 (76.0--89.0)     75.0 (65.5--79.2)   86.0 (80.6--91.0)     87.0 (81.0--90.0)

  Neutropenia --- no./total no. (%)[††](#t3fn8){ref-type="table-fn"}                     0/89                  0/28                0/38                  0/23

  Median platelet count (IQR) --- ×10^−9^/liter                                          155 (105--233)        186 (107--297)      125 (100--200)        162 (130--223)

  Platelet count \<80×10^−9^/liter --- no./total no. (%)                                 10/95 (11)            2/29 (7)            7/40 (18)             1/26 (4)

  Elevated proBNP level --- no./total no. (%)[‡‡](#t3fn9){ref-type="table-fn"}           74/82 (90)            22/23 (96)          34/34 (100)           18/25 (72)

  Elevated troponin level --- no./total no. (%)                                          63/89 (71)            15/26 (58)          27/38 (71)            21/25 (84)

  Median procalcitonin level (IQR) --- ng/dl                                             6.2 (2.2--19.7)       6.1 (2.2--15.8)     11.3 (4.4--24.8)      2.7 (0.4--18.5)

  Elevated procalcitonin level --- no./total no. (%)[§§](#t3fn10){ref-type="table-fn"}   60/65 (92)            19/20 (95)          29/29 (100)           12/16 (75)

  C-reactive protein level                                                                                                                               

  Median (IQR) --- mg/dl                                                                 21.9 (15.0--30.0)     20.6 (11.3--29.0)   21.0 (16.0--28.7)     28.3 (18.5--36.4)

  Distribution --- no./total no. (%)                                                                                                                     

  ≥3.0 mg/dl                                                                             98/98 (100)           31/31 (100)         41/41 (100)           26/26 (100)

  \>5.0 mg/dl                                                                            97/98 (99)            31/31 (100)         41/41 (100)           25/26 (96)

  \>10.0 mg/dl                                                                           85/98 (87)            24/31 (77)          38/41 (93)            23/26 (88)

  \>20.0 mg/dl                                                                           59/98 (60)            17/31 (55)          23/41 (56)            19/26 (73)

  Median fibrinogen level (IQR) --- mg/dl                                                624 (506--764)        551 (386--689)      596 (496--719)        766 (620--836)

  Fibrinogen level \>400 mg/dl --- no./total no. (%)                                     57/66 (86)            13/18 (72)          27/31 (87)            17/17 (100)

  Median [d]{.smallcaps}-dimer level (IQR) --- mg/liter                                  2.4 (1.2--3.7)        2.7 (1.7--4.4)      2.5 (1.3--3.6)        1.8 (0.8--3.3)

  [d]{.smallcaps}-dimer level \>0.55 mg/liter --- no./total no. (%)                      86/94 (91)            26/28 (93)          38/40 (95)            22/26 (85)

  Median ferritin level (IQR) --- ng/ml[¶¶](#t3fn11){ref-type="table-fn"}                522 (305--820)        412 (185--698)      613 (305--932)        540 (365--880)

  Ferritin level \>300 ng/ml --- no./total no. (%)                                       62/83 (75)            16/23 (70)          27/36 (75)            19/24 (79)

  Median albumin level (IQR) --- g/dl                                                    3.1 (2.5--3.6)        3.2 (2.5--3.6)      3.1 (2.5--3.5)        3.1 (2.6--3.8)

  Albumin level ≤3.0 g/dl --- no./total no. (%)                                          45/94 (48)            13/29 (45)          20/41 (49)            12/24 (50)

  Median LDH level (IQR) --- U/liter                                                     313 (267--380)        328 (273--426)      288 (256--342)        325 (283--465)

  LDH level ≥500 U/liter --- no./total no. (%)                                           6/69 (9)              2/19 (11)           2/31 (6)              2/19 (11)

  Median interleukin-6 level (IQR) --- pg/ml                                             116.3 (37.0--315.0)   80.0 (7.7--301.4)   215.0 (47.0--315.0)   111.0 (63.7--286.0)

  Interleukin-6 level ≥5.0 pg/ml --- no./total no. (%)                                   33/34 (97)            6/7 (86)            18/18 (100)           9/9 (100)

  Median ESR (IQR) --- mm/hr                                                             61.5 (43.0--77.5)     57.5 (46.0--72.0)   55.5 (38.0--75.5)     65.0 (59.0--88.0)

  ESR ≥40 mm/hr --- no./total no. (%)                                                    40/52 (77)            15/18 (83)          14/20 (70)            11/14 (79)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ESR denotes erythrocyte sedimentation rate, LDH lactate dehydrogenase, and proBNP pro--brain natriuretic peptide.

An elevated heart rate was coded as more than 160 beats per minute for an age of 0 to younger than 3 months, more than 150 for 3 to younger than 6 months, more than 130 for 6 to younger than 12 months, more than 125 for 1 to younger than 3 years, more than 115 for 3 to younger than 6 years, and more than 100 for older than 6 12 years.^[@r16]^

An elevated respiratory rate was coded as more than 60 breaths per minute for an age of 0 to younger than 3 months, more than 45 for 3 to younger than 6 months, more than 40 for 6 to younger than 12 months, more than 30 for 1 to younger than 3 years, more than 25 for 3 to younger than 6 years, more than 22 for 6 to younger than 12 years, and more than 18 for older than 12 years.^[@r16]^

Hypotension was defined as a systolic blood pressure of less than 60 mm Hg for an age of younger than 1 month, less than 70 mm Hg for 1 month to younger than 1 year, \[\<70+(2×the age in years)\] mm Hg for 1 to 10 years, and less than 90 mm Hg for older than 10 years.^[@r16]^

Patients were considered to have fever if there was either subjective or objective fever.

The normal ranges for selected variables are as follows: fibrinogen level, 200 to 400 mg per deciliter; [d]{.smallcaps}-dimer level, 0.20 to 0.55 mg per liter; albumin level, 3.4 to 5.4 g per deciliter; and erythrocyte sedimentation rate (ESR), 0 to 10 mm per hour.

Lymphopenia was defined as a lymphocyte level of less than 2.5% for an age of younger than 1 month, less than 4.0% for 1 to younger than 12 months, less than 3.0% for 1 to younger than 2 years, less than 2.0% for 2 to younger than 4 years, less than 1.5% for 4 to younger than 10 years, less than 1.2% for 10 to younger than 16 years, and less than 1.0% for 16 years or older.^[@r16]^

Neutropenia was classified as a neutrophil level of less than 1.0% for an age of younger than 6 months, less than 1.5% for 6 months to younger than 10 years, and less than 1.8% for 10 years or older.^[@r16]^

An elevated proBNP level (excluding children \<1 month of age) was classified as more than 1121 pg per milliliter for an age of 1 month to younger than 1 year, more than 675 pg per milliliter for 1 to younger than 2 years, more than 391 pg per milliliter for 2 to younger than 14 years, and more than 363 pg per milliliter for 14 years or older.^[@r17]^

An elevated procalcitonin level was classified as more than 0.5 ng per deciliter.^[@r18]^

The ferritin level was measured for children older than 2 months of age.

###### Clinical Course and Outcomes, According to Age Group.[\*](#t4fn1){ref-type="table-fn"}
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  -------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                              Overall\         0--5 Years\      6--12 Years\      13--20 Years\
                                                                        (N=99)           (N=31)           (N=42)            (N=26)
  --------------------------------------------------------------------- ---------------- ---------------- ----------------- -----------------
  Median time from symptom onset to hospital admission (IQR) --- days   4 (3--6)         4 (3--6)         5 (4--5)          4 (3--6)

  ICU admission --- no. (%)                                             79 (80)          19 (61)          38 (90)           22 (85)

  Median time to ICU entry (IQR) --- days                               0 (0--1)         0 (0--2)         0 (0--1)          0 (0--1)

  Median length of stay (IQR) --- days                                                                                      

  Overall                                                               6.0 (4.0--9.0)   6.0 (3.0--8.0)   6.0 (4.0--10.0)   6.5 (6.0--10.0)

  Among those discharged                                                6.0 (4.0--8.0)   5.0 (3.0--7.0)   4.0 (4.0--8.0)    6.0 (5.0--10.0)

  Therapy --- no. (%)                                                                                                       

  BiPAP or CPAP[†](#t4fn2){ref-type="table-fn"}                         7 (7)            1 (3)            3 (7)             3 (12)

  High-flow nasal cannula[†](#t4fn2){ref-type="table-fn"}               16 (16)          1 (3)            10 (24)           5 (19)

  Mechanical ventilation[†](#t4fn2){ref-type="table-fn"}                10 (10)          3 (10)           3 (7)             4 (15)

  ECMO                                                                  4 (4)            1 (3)            2 (5)             1 (4)

  Vasopressor support                                                   61 (62)          15 (48)          29 (69)           17 (65)

  Systemic glucocorticoids                                              63 (64)          16 (52)          30 (71)           17 (65)

  IVIG                                                                  69 (70)          26 (84)          30 (71)           13 (50)

  Systemic glucocorticoids and IVIG                                     48 (48)          15 (48)          25 (60)           8 (31)

  Diagnoses --- no. (%)[‡](#t4fn3){ref-type="table-fn"}                                                                     

  Kawasaki's disease or atypical Kawasaki's disease                     36 (36)          15 (48)          18 (43)           3 (12)

  Myocarditis                                                           52 (53)          12 (39)          21 (50)           19 (73)

  Shock                                                                 10 (10)          4 (13)           5 (12)            1 (4)

  Coronary-artery aneurysm                                              9 (9)            4 (13)           4 (10)            1 (4)

  Acute kidney injury                                                   10 (10)          3 (10)           4 (10)            3 (12)

  Death --- no. (%)                                                     2 (2)            1 (3)            1 (2)             0
  -------------------------------------------------------------------------------------------------------------------------------------------

BiPAP denotes bilevel positive airway pressure, CPAP continuous positive airway pressure, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, and IVIG intravenous immune globulin.

Therapies were not mutually exclusive; 2 patients received both BiPAP or CPAP and mechanical ventilation, and 3 patients received both high-flow nasal cannula and mechanical ventilation.

One patient received diagnoses of stroke and seizures.

[^1]: The members of the investigation team are listed in the [Supplementary Appendix](#ap1){ref-type="app"}, available at NEJM.org.
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